Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Blood (2022) 140 (Supplement 1): 4420–4422.

https://doi.org/10.1182/blood-2022-165942

Published: 2022

Journal Articles

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Blood (2022) 140 (Supplement 1): 4409–4411.

https://doi.org/10.1182/blood-2022-156390

Published: 2022

Journal Articles

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid C. Baz, Annette Juul Vangsted, Shir-Jing Ho, Simon J Harrison, Torben Plesner, Philippe Moreau, Simon D. Gibbs, Eva Medvedova, Muhammad Jalaluddin, Jeremy A. Ross, Leanne Lash Fleming, Yan Luo, Nizar Jacques Bahlis

Blood (2022) 140 (Supplement 1): 7261–7263.

https://doi.org/10.1182/blood-2022-163809

Published: 2022

Journal Articles

Acquired Loss of a Sex Chromosome Is a Positive Prognostic Factor for Patients with Multiple Myeloma Undergoing ASCT

Simon Husby, Morten Tulstrup, Mads Harsløf, Christian Nielsen, Marianne Antonius Jakobsen, Eva Kannik Hastrup, Lene Hyldahl Ebbesen, Mette Klarskov Andersen, Maroulio Pertesi, Björn Nilsson, Carsten Utoft Niemann, Agoston Gyula Szabo, Niels Frost Andersen, Niels Abildgaard, Kirsten Grønbæk, Annette Juul Vangsted

Blood (2022) 140 (Supplement 1): 4832–4833.

https://doi.org/10.1182/blood-2022-169982

Published: 2022

Journal Articles

A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Torben Plesner, Simon J Harrison, Hang Quach, Cindy H. Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert Hendricks, Teiko Sumiyoshi, Karen Miller, Eunpi Choi, Fredrik H. Schjesvold

Blood (2021) 138 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2021-147418

Published: 2021

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone Consolidation in Myeloma Patients with a Positive FDG PET/CT after Upfront Autologous Stem Cell Transplantation: A Phase II Study (CONPET)

Jakob Nordberg Nørgaard, Niels Abildgaard, Anna Lysén, Galina Tsykunova, Annette Juul Vangsted, Cristina João, Nora Remen, James P Connelly, Mona-Elisabeth R. Revheim, Fredrik H. Schjesvold

Blood (2021) 138 (Supplement 1): 3939.

https://doi.org/10.1182/blood-2021-147240

Published: 2021

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Blood (2019) 134 (Supplement_1): 693.

https://doi.org/10.1182/blood-2019-125120

Published: 2019

Journal Articles

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Blood (2019) 134 (Supplement_1): 601.

https://doi.org/10.1182/blood-2019-122141

Published: 2019

Journal Articles

Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study

Agoston Gyula Szabo, MD, Jonathan Thorsen, MD PhD, Charlotte Toftmann Hansen, MD PhD, Maja Ølholm Vase, MD PhD, Manuela Teodorescu, MD, Simon Bo Pedersen, MD, Simon Bertram Flæng, MD, Ulf Christian Frølund, MD, Annette Juul Vangsted, MD PhD, Torben Plesner, MD DSc

Blood (2019) 134 (Supplement_1): 5553.

https://doi.org/10.1182/blood-2019-124336

Published: 2019

Journal Articles

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Louise Redder, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD PhD, Henrik Gregersen, MD PhD, Niels Frost Andersen, MD PhD, Robert Schou Pedersen, MD PhD, Torben Plesner, MD DSc, Mikael Frederiksen, MD, Ulf Christian Frølund, MD, Carsten Helleberg, MD, Lene Kongsgaard Nielsen, MD PhD, Morten Salomo, MD PhD, Peter Gimsing, MD DMSc, Henrik Frederiksen, MD PhD Prof, Niels Abildgaard, MD

Blood (2019) 134 (Supplement_1): 1849.

https://doi.org/10.1182/blood-2019-128074

Published: 2019

Journal Articles

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

Nizar Bahlis, MD, Rachid Baz, MD, Simon Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, Hang Quach, MBBS, FRACP, FRCPA, MD, Shir-Jing Ho, MBBS, FRACP, FRCPA, MClinTrial Res, Annette Juul Vangsted, MD PhD, Philippe Moreau, MD, Simon Gibbs, FRACP, FRCPA, MBBS, Ahmed Hamed Salem, PhD FCP, Jeremy A. Ross, PhD, John Pesko, PhD, Sally Westrup, Jenny Vue, Paulo C. Maciag, MD PhD, Orlando F. Bueno, MD PhD, Jonathan L. Kaufman, MD

Blood (2019) 134 (Supplement_1): 925.

https://doi.org/10.1182/blood-2019-124407

Published: 2019

Journal Articles

A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma

Henrik Gregersen, MD, Niels Abildgaard, MD, Trung Hieu Do, MD, Ida Bruun Kristensen, MD, Ulf Christian Frølund, MD, Niels Frost Andersen, MD, Lene Kongsgaard Nielsen, MD, Christen Lykkegaard Andersen, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD

Blood (2017) 130 (Supplement 1): 3129.

https://doi.org/10.1182/blood.V130.Suppl_1.3129.3129

Published: 2017

Journal Articles

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Johan Lund, MD, Sigrid Karstorp, MD, Evren Alici, MD PhD, Astrid Gruber, MD PhD, Birgitta Lauri, MD, Cecilie Blimark, MD PhD, Agneta Swedin, MD PhD, Markus Hansson, MD PhD, Karin Forsberg, MD, Lucia Ahlberg, MD, Carlsson Conny, MD, Anders Waage, MD PhD, Peter Gimsing, Annette Juul Vangsted, MD PhD, Ulf Christian Frølund, MD, Mats Hardling, Ulf-Henrik Mellqvist, MD PhD, Hareth Nahi

Blood (2015) 126 (23): 3047.

https://doi.org/10.1182/blood.V126.23.3047.3047

Published: 2015

Journal Articles

The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis

Blood (2014) 124 (21): 3421.

https://doi.org/10.1182/blood.V124.21.3421.3421

Published: 2014

Journal Articles

Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium

Blood (2014) 124 (21): 2044.

https://doi.org/10.1182/blood.V124.21.2044.2044

Published: 2014

Journal Articles

An Inborn Variation In The Anaplastic Lymphoma Receptor Tyrosine Kinase Gene ( ALK ) Increases Risk Of MAF (Musculoaponeurotic Fibrosarcoma Oncogene Homolog) High Expressing Myeloma

Annette Juul Vangsted, MD, Stephen Erickson, Ph.D, Naveen Sanath Kumar, MD, Elizabeth Ann Coleman, PhD, Erming Tian, PhD, Julia Goodwin, PhD, Joshua Epstein, DSc, Owen Stephens, Ph.D., Bart Barlogie, MD, PhD, Christoph Heuck, MD

Blood (2013) 122 (21): 1908.

https://doi.org/10.1182/blood.V122.21.1908.1908

Published: 2013

Journal Articles

Chemotherapy-Induced Oral Mucositis: 11 SNPs Implicated In GWAS Of 972 Patients With Multiple Myeloma

Elizabeth Ann Coleman, PhD, Jeannette Y Lee, Ph.D., Stephen Erickson, Ph.D, Julia Goodwin, PhD, Marjorie Beggs, PhD, Naveen Sanathkumar, MD, Daohong Zhou, MD, Kent McKelvey, MD, Vinay Raj, Ph.D., Senu Apewokin, MD, Owen Stephens, Ph.D., Carol Enderlin, Ph.D., Annette Juul Vangsted, MD, Patty Reed, MS, Elias J. Anaissie, MD

Blood (2013) 122 (21): 3316.

https://doi.org/10.1182/blood.V122.21.3316.3316

Published: 2013

NARROW

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Acquired Loss of a Sex Chromosome Is a Positive Prognostic Factor for Patients with Multiple Myeloma Undergoing ASCT

A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Carfilzomib-Lenalidomide-Dexamethasone Consolidation in Myeloma Patients with a Positive FDG PET/CT after Upfront Autologous Stem Cell Transplantation: A Phase II Study (CONPET)

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma

A Randomized Placebo-Controlled Phase II Study of Clarithromycin or Placebo Combined with VCD Induction Therapy Prior to High-Dose Melphalan with Stem Cell Support in Patients with Newly Diagnosed Multiple Myeloma

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis

Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium

An Inborn Variation In The Anaplastic Lymphoma Receptor Tyrosine Kinase Gene ( ALK ) Increases Risk Of MAF (Musculoaponeurotic Fibrosarcoma Oncogene Homolog) High Expressing Myeloma

Chemotherapy-Induced Oral Mucositis: 11 SNPs Implicated In GWAS Of 972 Patients With Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only